Tiresias: Whither current pathology?, page-2

I think autopsies and histological confirmation of pathology are still going to be required. The confocal microscopy will be an adjunct which gives real time assistance which is especially useful in surgery or as a screening tool. But it isn't going to be 100% accurate although it might be pretty good in experienced hands especially with software enhancements. In actual fact I think that pathology will be using DNA sequencing of cancer as a new tool to help choose the best treatment of malignancy, since we now know that cancers arising in the same organ are not homogeneous and some will respond better to one treatment or another. Having a library of the mutations will eventually allow a tailor made treatment for say hepatocellular carcinoma or breast cancer or other malignancies.
So Optiscans devices will be part of a suite of useful tools, but I don't see it actually replacing the existing ones.

But first step is to validate it as a tool. I am curious to see what the market reaction will be if the trial results are good and it received FDA approval for the 510k.